HR

Holger Reithinger

Venture Capital Investor

Greater Munich Metropolitan Area

Investor
VC

Invests in

Stages:

Series A
Seed

Locations:

Munich, Germany

  • Min Investment:

    $100,000.00

  • Max Investment:

    $5,000,000.00

  • Target Investment:

    $1,500,000.00

Skills

Board Level
Board Administration
Board Governance
Board Operation
Venture Capital
Early Stage
Biopharma
Biopharmaceuticals
Biotechnology
Commercialization
Pharmaceutical Industry
Investments
Technology Transfer
Due Diligence
Angel Investing
Mergers & Acquisitions
Start-ups
Strategy
Lifesciences
Product Development

Education

Investments

OMEICOS Therapeutics

Series C

Total Funding: $27M

Gotham Therapeutics

Series A

Total Funding: $54M

Allecra Therapeutics

Series A

Total Funding: $45M

Curetis

Series A

Total Funding: $31M

Santaris Pharma

Series C

Total Funding: $42M

Agendia

Series D

Total Funding: $57M

Work Experience

BIO Deutschland e. V.

2024

  • Coordinator

    2024

    I am co-heading the working group Finance & Taxes at BIO Germany.

Forbion - Impacting the future of medicine

2010

  • Partner

    2010

High-Tech Gründerfonds

2017

  • Member of the Investment Committee

    2017

Allecra Therapeutics

2013 - 2023

  • Board Member

    2013 - 2023

Seamless Therapeutics

2022 - 2023

  • Board Observer

    2022 - 2023

OMEICOS Therapeutics GmbH

2018 - 2022

  • Board Member

    2018 - 2022

CatalYm GmbH

2016 - 2021

  • Chairman Of The Board

    2016 - 2021

Gotham Therapeutics

2018 - 2020

  • Board Director

    2018 - 2020

    Gotham is part of New York City’s rapidly growing biopharma community with a subsidiary in one of Europe’s leading life science clusters near Munich, Germany. Forbion co-led the $54 million Series A financing round.

Cellnovo Group SA

2014 - 2018

  • Member of the Board

    2015 - 2018

  • Board Director

    2014 - 2015

Curetis Group

2015 - 2018

  • Aufsichtsrat

    2015 - 2018